Stock Quote
QLT Inc. (QLTI.O) (Nasdaq)
sector: Healthcare .
industry: Pharmaceuticals - Generic & Specialty ยท
View QLTI on other exchanges
$3.67
3:16pm EST
-0.54%
$3.69
$3.71
143,490
$3.79
$3.66
$4.50
$1.40
0.44
314,151
QLTI.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Clarke, C. Boyd | Chairman of the Board | -- |
| Butchofsky, Robert | President, Chief Executive Officer, Director | 996,175 |
| Nelson, Cameron | Chief Financial Officer, Vice President - Finance | 628,276 |
Profile
QLT Inc. (QLT), is a global biopharmaceutical company engaged in the business of discovering, developing and commercialization of therapies. QLT has two commercial products, Visudyne and Eligard. Visudyne utilizes photodynamic therapy (PDT), to treat the eye disease known as wet age related macular... Full Description
Company Address
QLT Inc.
887 Great Northern Way
Vancouver BC V5T 4T5
P: +1604.7077000
F: +1604.7077001
887 Great Northern Way
Vancouver BC V5T 4T5
P: +1604.7077000
F: +1604.7077001
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Genentech, Inc. | -- | -- |
| Novartis AG | CHF55.15 | +1.20 |
| Alcatel-Lucent | €2.40 | -0.06 |
| QLTI.O | Industry | |
|---|---|---|
| P/E(TTM) | 45.59 | 3.57 |
| P/S(TTM) | 2.84 | 0.57 |
| ROI(TTM) | 1.73 | 1.86 |
| ROE(TTM) | 1.75 | 2.51 |
| Consensus Recommendation | Hold |
|---|---|
| EPS Est. (Current Period) | -- |
| EPS Est. (Current Year) | -0.03 |
| Total Revenue | $9.41M |
| Net Income | $2.39M |
| EPS | $0.04 |
